Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (NQ: ONCY )

2.190 +0.070 (+3.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 470,560
Open 2.140
Bid (Size) 2.150 (15)
Ask (Size) 2.230 (17)
Prev. Close 2.120
Today's Range 2.100 - 2.230
52wk Range 1.090 - 3.394
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress... 
Via FinancialNewsMedia
Pancreatic Cancer Battle Boosted by $200M VC Firm
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death

Performance

YTD
+36.87%
+36.87%
1 Month
-6.01%
-6.01%
3 Month
-13.10%
-13.10%
6 Month
+76.61%
+76.61%
1 Year
+69.77%
+69.77%

More News

Read More
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
Via FinancialNewsMedia
Exposures Product Safety
Oncolytics Biotech's Earnings: A Preview
Via Benzinga
3 Under-$20 Stocks to Buy for Explosive Returns
Via InvestorPlace
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Oncolytics Biotech’s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Via FinancialNewsMedia
Expert Ratings for Oncolytics Biotech
Via Benzinga
Earnings Scheduled For August 14, 2023
Via Benzinga
5 Analysts Have This to Say About Oncolytics Biotech
Via Benzinga
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
Via FinancialNewsMedia
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
Via FinancialNewsMedia
Oncolytics Biotech: Q1 Earnings Insights
Via Benzinga
Oncolytics Biotech's Earnings: A Preview
Via Benzinga
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
Via FinancialNewsMedia
Exposures COVID-19
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
Via FinancialNewsMedia
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Via FinancialNewsMedia
Exposures Product Safety
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
Via FinancialNewsMedia
Exposures Product Safety
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
Via Benzinga
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
Via FinancialNewsMedia
Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030
Via FinancialNewsMedia
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
Via FinancialNewsMedia
Exposures Product Safety
Earnings Scheduled For May 5, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.